InsulinAPP Application Protocol for the Inpatient Management of Type 2 Diabetes on a Hospitalist-managed Ward: a Retrospective Study
Overview
Authors
Affiliations
Introduction: We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital.
Subjects And Methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were evaluated.
Results: A total of 147 T2D individuals (23% medicine and 77% surgery) were included (mean age 62.3 ± 12.7 years, HbA1c: 8.3 ± 3.0%). The initial insulin regimen was 50% bolus-correction, 47% basal-bolus and 3% with sliding scale insulin. During hospitalization, 71% patients required a bolus-basal regimen. In the first 10 days of the protocol, 71% BG measurements were between 70-180 mg/dL and 26% patients experienced one or more episodes of hypoglycemia < 70 mg/dL, and 5% with BG < 54 mg/dL.
Conclusion: The results of this retrospective study indicate the InsulinAPP application using human insulin formulations was effective and safe for the management of hyperglycemia on a hospitalist-managed ward, with more than 70% BG measurements within the therapeutic range and a low rate of hypoglycemia.
Lavinas-Jones J, Toyoshima M, Mesquita L, Nery M, Feitosa A J Diabetes Sci Technol. 2025; 19(2):587-589.
PMID: 39797678 PMC: 11724393. DOI: 10.1177/19322968241306443.
Camara de Souza A, Toyoshima M, Cukier P, Lottenberg S, Bolta P, Lima E J Diabetes Sci Technol. 2024; :19322968241268352.
PMID: 39096188 PMC: 11571349. DOI: 10.1177/19322968241268352.
Lin J, Zhang J, Liang B, Lin J, Wang N, Lin J Diabetol Metab Syndr. 2024; 16(1):2.
PMID: 38172998 PMC: 10763004. DOI: 10.1186/s13098-023-01242-3.
Zhang X, Yan D, Du T, Zhao Y, Zhang J, Zhang T Diabetol Metab Syndr. 2023; 15(1):243.
PMID: 38008775 PMC: 10680246. DOI: 10.1186/s13098-023-01193-9.